Immediate Impact
3 from Science/Nature 62 standout
Citing Papers
Cardiovascular Disease Risk Among Cancer Survivors
2022 Standout
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
2022 Standout
Works of C Schulman being referenced
4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer
2000
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| C Schulman | 241 | 51 | 61 | 63 | 13 | 303 | |
| ROBERT E. GERSTENBLUTH | 227 | 94 | 58 | 71 | 13 | 371 | |
| Moon Ki Jo | 239 | 54 | 37 | 15 | 17 | 314 | |
| Deborah T. Glassman | 95 | 62 | 23 | 51 | 15 | 304 | |
| Simone Giona | 196 | 107 | 56 | 47 | 16 | 350 | |
| Bradley Holland | 156 | 67 | 77 | 47 | 19 | 292 | |
| Roger O. Plail | 72 | 87 | 34 | 90 | 11 | 323 | |
| P. A. Gammelgaard | 155 | 93 | 31 | 23 | 21 | 267 | |
| C. R. Nyman | 96 | 166 | 49 | 35 | 19 | 343 | |
| E. Stewart Geary | 216 | 108 | 112 | 37 | 8 | 327 | |
| R Fourcade | 196 | 30 | 120 | 80 | 16 | 310 |
All Works
Loading papers...